Nasus Pharma Ltd (NSRX) Form 6-K — Jul 28, 2026
Nasus Pharma appointed pharmaceutical industry veteran Brendan P. O'Grady as Chief Executive Officer, effective July 27, 2026. Mr. O'Grady succeeds Dan Teleman, who resigned from his position as CEO and director following a mutual separation agreement.
Key figures
- Ns002 Topline Data
- Q1 2027
- Ns002 Pivotal Trial
- Q4 2026
- Ns002 Market Opportunity
- $2 billion
- Ogradey Experience Years
- 35
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.